J. Johannes

发表

Biomimetic macrocycle-forming Diels-Alder reaction of an iminium dienophile: synthetic studies directed toward gymnodimine.

Steve Wenglowsky, Y. Kishi, J. Johannes, 2005, Organic letters.

A Unified and Practical Method for Carbon-Heteroatom Cross-Coupling via Nickel/Photo Dual Catalysis.

J. Johannes, Randolph A Escobar, 2020, Chemistry.

Effects of Molecular Oxygen, Solvent, and Light on Iridium-Photoredox/Nickel Dual-Catalyzed Cross-Coupling Reactions.

B. Aquila, A. Varela-Álvarez, Daniel W. Robbins, 2015, The Journal of organic chemistry.

Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl Radicals.

B. Aquila, M. Frenette, Daniel W. Robbins, 2016, Journal of the American Chemical Society.

Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis

Regina Barzilay, Ola Engkvist, Tommi Jaakkola, 2020, Journal of medicinal chemistry.

Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross-Coupling of Primary Aryl Amines with Aryl Halides.

S. Tentarelli, B. Aquila, M. Frenette, 2016, Angewandte Chemie.

Mouse Red Blood Cell–Mediated Rare Xenobiotic Phosphorylation of a Drug Molecule Not Intended to Be a Kinase Substrate

Shenghua Wen, P. Doig, E. Gangl, 2017, Drug Metabolism and Disposition.

Practical Syntheses of [2,2′-Bipyridine]bis[3,5-Difluoro-2-[5-(Trifluoromethyl)-2-Pyridinyl]phenyl]iridium(III) Hexafluorophosphate, [Ir{dF(CF3)ppy}2(bpy)]PF6 and [4,4′-bis(tert-butyl)-2,2′-bipyridine]bis[3,5-Difluoro-2-[5-(Trifluoromethyl)-2-Pyridinyl]ph

J. Johannes, Martins S Oderinde, 2018, Organic Syntheses.

Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors

Edward W. Tate, James S. Scott, Charlie N Saunders, 2020, ACS chemical biology.

Reductive Radical Conjugate Addition of Alkyl Electrophiles Catalyzed by a Cobalt/Iridium Photoredox System.

J. Johannes, Randolph A Escobar, 2021, Organic letters.

Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides

Mikhail O. Konev, T. A. McTeague, J. Johannes, 2018, ACS Catalysis.

Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors

Toan B. Nguyen, M. Haddrick, A. Ferguson, 2018, ChemMedChem.

Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.

A. Ferguson, P. Lyne, N. Larsen, 2018, Bioorganic & medicinal chemistry letters.

Multi-omic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation

Ralitsa R. Madsen, A. Toker, N. Gray, 2022, bioRxiv.

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

David A. Scott, Edward W. Tate, J. Dry, 2018, Cancer research.

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

David A. Scott, S. Kazmirski, A. Ferguson, 2015, Bioorganic & medicinal chemistry letters.

Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

S. Kazmirski, Nancy Su, D. Ogg, 2015, ACS medicinal chemistry letters.

Photoredox-Mediated, Nickel-Catalyzed Trifluoromethylthiolation of Aryl and Heteroaryl Iodides.

J. Johannes, Avipsa Ghosh, Eric R. King, 2021, The Journal of organic chemistry.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

J. A. Hendricks, David M. Wilson, S. Kazmirski, 2018, Nature Communications.

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.

Fiona Pachl, A. Pike, M. O’Connor, 2021, Journal of medicinal chemistry.

Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.

C. Chuaqui, J. Tucker, N. Larsen, 2012, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.

Allan Wu, Edward Hennessy, Jon Read, 2013, Journal of medicinal chemistry.

Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.

David A. Scott, S. Kazmirski, P. Lyne, 2016, Bioorganic & medicinal chemistry letters.

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.

Christoph E. Dumelin, S. Kazmirski, A. Keefe, 2017, ACS medicinal chemistry letters.

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

M. O’Connor, S. Fawell, Glen Hawthorne, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles.

Nichola L. Davies, E. Chiarparin, M. Lamb, 2019, Journal of medicinal chemistry.

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Fiona Pachl, M. O’Connor, Glen Hawthorne, 2018, Experimental and Molecular Therapeutics.

Photoredox Mediated Nickel Catalyzed Cross‐Coupling of Thiols with Aryl and Heteroaryl Iodides via Thiyl Radicals.

B. Aquila, M. Frenette, Daniel W. Robbins, 2016 .

Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases.

C. Chuaqui, Hai‐Jun Zhang, Audrey Molina, 2014, Bioorganic & medicinal chemistry letters.

Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases.

C. Chuaqui, Hai‐Jun Zhang, Audrey Molina, 2014, Bioorganic & medicinal chemistry letters.

Halide Noninnocence and Direct Photoreduction of Ni(II) Enables Coupling of Aryl Chlorides in Dual Catalytic, Carbon-Heteroatom Bond-Forming Reactions.

P. Thordarson, Chern-Hooi Lim, G. Miyake, 2023, Journal of the American Chemical Society.

Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1

D. Hargreaves, E. Chiarparin, S. Degorce, 2023, Proceedings of the National Academy of Sciences of the United States of America.

Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers

S. Kazmirski, J. Tyner, D. Hargreaves, 2017 .